Mostrando 5 resultados de: 5
Subtipo de publicación
Article(5)
Publisher
Cancer Immunology, Immunotherapy(1)
Clinical Cancer Research(1)
Frontiers in Pharmacology(1)
Journal of Immune Based Therapies and Vaccines(1)
OncoImmunology(1)
Origen
scopus(5)
Biomarkers related to immunosenescence: relationships with therapy and survival in lung cancer patients
ArticleAbstract: Purpose: There are well-known alterations occurring within the immune system with aging. CollectivelPalabras claves:cancer vaccine, Immunosenescence, Immunosenescence markers, Non-small cell lung cancerAutores:Fuentes K.P., García Verdecia B., González A., Lage Davila A., Luaces P.L.o., Mazorra Z., Neninger Vinageras E., Popa X., Saavedra Hernández D., Tania CrombetFuentes:scopusAnti-EGF antibodies as surrogate biomarkers of clinical efficacy in stage IIIB/IV non-small-cell lung cancer patients treated with an optimized CIMAvax-EGF vaccination schedule
ArticleAbstract: We previously reported that CIMAvax-EGF vaccine is safe, immunogenic and efficacious to treat advancPalabras claves:antibodies affinity, cancer vaccine, EGF, NSCLC, surrogate biomarkerAutores:Alvarez K., Carmen Elena Viada, Fuentes K.P., García Verdecia B., González A., Gonzalez Z., Huerta V., Mazorra Z., Neninger Vinageras E., Popa X., Rodríguez P.C., Tania CrombetFuentes:scopusA Phase III Clinical Trial of the Epidermal Growth Factor Vaccine CIMAvax-EGF as Switch Maintenance Therapy in Advanced Non-Small Cell Lung Cancer Patients
ArticleAbstract: Purpose: EGFR is a well-validated target for patients with non-small cell lung cancer (NSCLC). CIMAvPalabras claves:Autores:Acosta S.C., Aguilera N., Alonso L., Amador R.M., Arzuaga L., Cala M., Carmen Elena Viada, Catala M., Crespo T., De La Torre A.V., Fleytas R., Flores Y.I., Futiel N., García Verdecia B., Lage Davila A., Luaces P.L.o., Marrero Miragaya M.A., Martínez O., Mazorra Z., Mendoza S., Neninger Vinageras E., Otero Y., Parra J., Pomares Y., Popa X., Reyes D., Rodríguez G., Rodríguez P.C., Romero G.N., Sabates T., Santiesteban E.R., Sierra P., Tania Crombet, Vello L.Fuentes:scopusSafety and immunogenicity of a human epidermal growth factor receptor 1 (HER1)-based vaccine in prostate castration-resistant carcinoma patients: A dose-escalation phase I study trial
ArticleAbstract: Metastatic castration-resistant prostate cancer (CRPC) remains incurable due to the lack of effectivPalabras claves:Human epidermal growth factor receptor, Immunogenicity, Prostate cancer, safety, Therapeutic vaccineAutores:Aira L.E., Bárbara Wilkinson, Caballero I., Casacó Parada A.R., Coba K., González J.G., González N., Lavastida A., Luaces P.L.o., Macías A.E., Mazorra Z., Mesa M., Popa X., Rivero J., Sanchez B., Santiesteban Y., Suárez E., Tania Crombet, Troche M.Fuentes:scopusSafety, immunogenicity and preliminary efficacy of multiple-site vaccination with an Epidermal Growth Factor (EGF) based cancer vaccine in advanced non small cell lung cancer (NSCLC) patients
ArticleAbstract: The prognosis of patients with advanced non small cell lung (NSCLC) cancer remains dismal. EpidermalPalabras claves:Autores:Carmen Elena Viada, García Verdecia B., González G., Lage Davila A., Luaces P.L.o., Montero E., Neninger Vinageras E., Popa X., Rodríguez P.C., Tania CrombetFuentes:scopus